ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Early Rheumatoid Arthritis"

  • Abstract Number: 1034 • 2013 ACR/ARHP Annual Meeting

    The Part Of Function (Health assessment Questionnaire) In The SF-6D and EQ-5D Utility Measures Varies Over Time In Early Arthritis (ESPOIR cohort): Questionable Validity Of Deriving Quality Adjusted Life Years From HAQ

    Cécile Gaujoux-Viala1, Anne-Christine Rat2, Kossar Hosseini3, Rene-Marc Flipo4, Francis Guillemin3 and Bruno Fautrel5, 1EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 2Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, 3CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 4Rheumatology, University Hospital Lille, Lille, France, 5Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France

    Background/Purpose: There is growing emphasis on the cost-effectiveness of treating early arthritis (EA). As few studies directly record the utility measures needed for economic analyses,…
  • Abstract Number: 1960 • 2013 ACR/ARHP Annual Meeting

    Combination Of Magnetic Resonance Imaging-Proven Osteitis With 2010 RA Classification Criteria Improves The Diagnostic Probability Of Early Rheumatoid Arthritis Whose Disease Duration Less Than 6 Months

    Mami Tamai1,2, Junko Kita3, Yoshikazu Nakashima4, Ayako Nishino4, Takahisa Suzuki4, Yoshiro Horai4, Akitomo Okada5, Tomohiro Koga6, Shin-ya Kawashiri4,7, Naoki Iwamoto4, Kunihiro Ichinose4, Kazuhiko Arima7, Satoshi Yamasaki8, Hideki Nakamura4, Tomoki Origuchi9, Masataka Uetani10, Aya Fukushima10, Kiyoshi Aoyagi7, Katsumi Eguchi11 and Atsushi Kawakami4, 1Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, 2Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 6Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 9Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 10Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 11Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: In the articles describing the 2010 rheumatoid arthritis (RA) classification criteria , it is stated that additional evidence of joint injury from imaging techniques such…
  • Abstract Number: 870 • 2013 ACR/ARHP Annual Meeting

    How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort

    Gaël Mouterde1, Cédric Lukas2, Nathalie Rincheval3, Alain Saraux4, Philippe Dieude5 and Bernard Combe6, 1Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, 2Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 3Institut Universitaire de Recherche Clinique, Montpellier, France, 4Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 5Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, 6Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France

    Background/Purpose: To describe disease course of patients without rheumatoid factor (RF) and anti-citrullinated protein auto-antibodies (ACPA) in an inception cohort of early arthritis patients. To determine…
  • Abstract Number: 1962 • 2013 ACR/ARHP Annual Meeting

    The Value Of the  2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria For The Prognosis Of Early Arthritis: Evaluation Of Erosion Development With Ultrasonography

    Nevsun Inanc1, Fatma Alibaz-Oner2, Meryem Can3, Pamir Atagündüz2 and Haner Direskeneli2, 1Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 3Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: The 2010  ACR/EULAR Rheumatoid Arthritis(RA) classification criteria was developed to diagnose the early arthritis patients who will progress destructive disease and to start  early…
  • Abstract Number: 833 • 2013 ACR/ARHP Annual Meeting

    Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk?

    Rishi Desai1, Jaya Rao2, Richard Hansen3, Gang Fang4, Matthew Maciejewski5 and Joel Farley4, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 2Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 3Harrison School of Pharmacy, Auburn University, Auburn, AL, 4University of North Carolina, Chapel Hill, NC, 5Duke University, Durham, NC

    Background/Purpose: Atherosclerosis is known to be accelerated in rheumatoid arthritis (RA) patients resulting in an increased cardiovascular (CV) risk. Structural damage to joints occurs aggressively…
  • Abstract Number: 1820 • 2013 ACR/ARHP Annual Meeting

    Assessing 24-Hour Physical (In)Activity and Sleep In People With Early Rheumatoid Arthritis

    Christopher Feehan1, Eric C. Sayre2, Erin Carruthers2 and Lynne M. Feehan3, 1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Physical Therapy, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: For people with inflammatory arthritis, the health benefits of physical activity (PA) and negative impact of sedentary lifestyle are clear. However, it is unclear…
  • Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients

    L. Heimans1, K.V.C. Wevers-de Boer1, G. Akdemir1, H.K Ronday2, T.H.E. Molenaar3, J. H. L. M. Van Groenendael4, A.J. Peeters5, I. Speyer6, G. Collee7, P.B. de Sonnaville8, B.A. Grillet9, T.W.J. Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, Netherlands, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, Netherlands, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…
  • Abstract Number: 1789 • 2013 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial

    Karen Hambardzumyan1, Saedis Saevarsdottir2, Rebecca Bolce3, Kristina Forslind4, Sofia Ernestam5, Ingemar F. Petersson6, Pierre Geborek7, David Chernoff3, Douglas J. Haney3, Eric H. Sasso3 and Ronald F van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Crescendo Bioscience Inc., South San Francisco, CA, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, 6Lund University, Lund, Sweden, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 8ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: In early rheumatoid arthritis (eRA), clinical and radiographic predictors would be very useful for optimizing available therapies. Individual biomarkers and their combinations, such as…
  • Abstract Number: 710 • 2013 ACR/ARHP Annual Meeting

    Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4+ T Cells In Early Rheumatoid Arthritis

    Amy E. Anderson1, Christine Routledge1, Philip Mawson2, John D. Isaacs3 and Arthur G. Pratt3, 1Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, 2Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease, caused by a breakdown in self tolerance. Robust biomarkers are needed which, as well having…
  • Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany

    Malte Wolff1, Zheng-Yi Zhou2, James Signorovitch2, James W. Shaw3 and Arijit Ganguli3, 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 2Analysis Group, Inc., Boston, MA, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
  • Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting

    Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort

    Cécile Gaujoux-Viala1, Laure Gossec2, Maxime Dougados3, Francis Guillemin4 and Bruno Fautrel5, 1EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, 2Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, 3Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 4CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 5Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France

    Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology